3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
66
Neutropenia
16
Triple Negative Breast Neoplasms
8
Breast Neoplasms, Male
6
Inflammatory Breast Neoplasms
4
Ovarian Neoplasms
3
Lung Neoplasms
3
Neoplasms
2
Febrile Neutropenia
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Pain
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Early Stage Breast Cancer
1
Fever
1
Early Stage Breast Cancer
1
Colorectal Neoplasms
1
Chemotherapy-Induced Febrile Neutropenia
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Diseases
1
Breast Cancer Metastatic
1
Breast Cancer Female
1
Adenocarcinoma
1
Interventions
Trastuzumab
33
pertuzumab
18
Docetaxel
16
pyrotinib
15
Paclitaxel
7
Capecitabine
6
tucatinib
5
Carboplatin
5
Ado-Trastuzumab Emtansine
4
trastuzumab deruxtecan
3
neratinib
3
atezolizumab
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
pegfilgrastim
1
palbociclib
1
margetuximab
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Hospital Information Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
pegfilgrastim
×
Breast
×
Clear all
NCT03571633
2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2
Active not recruiting
90 enrolled